Category stocks

Protalix Biotherapeutics Give Q1 Results

Protalix BioTherapeutics press release (PLX): Q1 GAAP EPS of $0.22 - Revenue of $33.75M (+233.8% Y/Y) - The Company reaffirms its previously stated 2026 revenue expectations: - Total revenue in 2026 to range from approximately $78.0 million to $83.0 million including the $25.0...